BNP Paribas Asset Management
CAPR icon

BNP Paribas Asset Management’s Capricor Therapeutics CAPR Stock Holding History

BNP Paribas Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.5K Buy
+838
New +$22.3K ﹤0.01% 1952
2025
Q3 		– Sell
-448
Closed -$4K – 1897
2025
Q2 		$4K Buy
+448
New +$4.73K ﹤0.01% 2070

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BNP Paribas Asset Management's CAPR Position: Q1 2026 in Review

BNP Paribas Asset Management opened a new position in Capricor Therapeutics (CAPR) in Q1 2026: 838 shares worth $25.5K. The stake represents ﹤0.01% of the portfolio and ranks #1952 among its holdings. This is a return to the name: BNP Paribas Asset Management previously reported a position in CAPR as recently as Q2 2025.

BNP Paribas Asset Management first reported a position in CAPR in Q2 2025 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • BNP Paribas Asset Management held 838 shares of Capricor Therapeutics worth $25.5K as of Q1 2026.
  • Capricor Therapeutics was a new BNP Paribas Asset Management position in Q1 2026.
  • Capricor Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1952 holding.
  • BNP Paribas Asset Management first reported a position in Capricor Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.